The persistence of latent HIV-1 remains a major challenge in therapeutic efforts to eradicate infection. Prior attempts at purging viral reservoirs have included T cell mitogens or histone deacetylase inhibitors (HDACIs) with limited success in reducing the viral reservoir, underscoring the need for additional approaches that promote viral reactivation. This proposal is motivated by our recent discovery [1] that a small molecule, JQ1, initially identified as a potent bromodomain-4 (Brd4) antagonist and cancer suppressor, potently upregulates latent and induced HIV proviral expression in cell lines and primary CD4+ T cells. In addition, JQ1 suppresses systemic inflammatory cytokine production in mice acutely exposed to endotoxin and suppresses T cell activation genes in primary CD4+ T cells. JQ1 therefore represents a novel compound with desirable features and translational utility. Our overall hypothesis is that JQ1 promotes viral reactivation and suppresses NF-kB driven gene expression by modulating Brd4 activity. As a result of interfering with Brd4 activity at the HIV promoter, JQ1 may increase access of the viral Tat protein to the host positive transcriptional elongation factor (P-TEFb). At cytokine gene promoters, we hypothesize that JQ1 interferes with acetylated p65/RelA interaction with Brd4 resulting in declines in NF- B driven cytokine gene expression, but not NFAT driven gene expression. To address our hypothesis, we propose a translational program to characterize this compound's effect on HIV proviral reactivation and on cytokine gene expression in latent T cell lines, an in vitro latency model for primary T cells and in resting CD4+ T cells from infected individuals receiving effective ART.

Public Health Relevance

Despite the profound success of HAART, viral reservoirs and chronic inflammation persist, necessitating lifelong treatment and increased risk for inflammation associated comorbidities. We describe a proposal to evaluate a novel compound JQ1 that displays potent HIV reactivation and cytokine gene suppression. This may have translational relevance for novel strategies to purge viral reservoirs, within a favorable context of inflammatory cytokine suppression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI102844-01A1
Application #
8701801
Study Section
Special Emphasis Panel (ZRG1-AARR-E (02))
Program Officer
Voulgaropoulou, Frosso
Project Start
2013-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$623,372
Indirect Cost
$258,115
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118